Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04998552

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Led by Capital Health System, Inc · Updated on 2023-03-31

10

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.

CONDITIONS

Official Title

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to sign the informed consent and understand the consenting process
  • Completed neoadjuvant chemotherapy regimen
  • Patient is 18 years of age and older
  • Eastern Cooperative Oncology Group (ECOG) Status of 0-1
  • Diagnosis of Stage I to Stage III pancreatic cancer confirmed by cytology or pathology based on imaging or exploratory laparoscopic surgery, with low arterial involvement and no aorta involvement
  • Eligible for IMRT or SBRT and approved for radiation therapy by multidisciplinary tumor board
  • No evidence of disease progression to distant metastasis based on NCCN guidelines
  • Negative pregnancy test
Not Eligible

You will not qualify if you...

  • Pregnant or lactating female patients not willing to use highly effective birth control from screening to 6 months after last radiation dose
  • Resectable pancreatic cancer
  • Unresectable pancreatic cancer
  • Unable to tolerate general anesthetic with full skeletal muscle blockade
  • Presence of implanted cardiac pacemakers, defibrillators, electronic devices, or metal parts in thoracic cavity
  • Life expectancy less than 1 year

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Capital Health Medical Center-Hopewell

Pennington, New Jersey, United States, 08534

Actively Recruiting

Loading map...

Research Team

S

Shirnett Williamson, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma | DecenTrialz